- Aleksic, V. and Knezevic, P., 2014. Antimicrobial and antioxidative activity of extracts and essential oils of Myrtus communis L. Microbiological Research, 169(4): 240-254.
- Alipour, G., Dashti, S. and Hosseinzadeh, H., 2014. Review of pharmacological effects of Myrtus communis L. and its active constituents. Phytotherapy Research, 28(8): 1125-1136.
- Amensour, M., Sendra, E., Abrini, J., Bouhdid, S., Perez-Alvarez, J.A. and Fernandez-Lopez, J., 2009. Total phenolic content and antioxidant activity of myrtle (Myrtus communis) extracts. Natural Product Communications, 4: 819-824.
- Avci, M.E., Arslan, F., Çiftçi, Ş., Ekiz, A., Tüten, A., Yildirim, G. and Madazli, R., 2015. Role of spiramycin in prevention of fetal toxoplasmosis. Journal of Maternal-Fetal & Neonatal Medicine, 29(13): 2073-2076.
- Azadbakht, M., Ziaei, H., Abdollahy, F. and Shabankhani, B., 2004. Effect of methanolic essence and extract of Myrtus communis on Trichomonas vaginalis. Journal of Guilan University of Medical Sciences, 12(48): 8-13.
- Baharvand-Ahmadi, B., Bahmani, M., Naghdi, N., Saki, K., Baharvand-Ahmadi, S. and Rafieian-Kopaei, M., 2015. Review on phytochemistry, therapeutic and pharmacological effects of myrtus (Myrtus communis). Der Pharmacia Lettre, 7(11): 160-165.
- Barati, M., Sharifi, I. and Sharififar, F., 2015. In vitro evaluation of anti-leishmanial activities of Zataria multiflora Boiss, Peganum harmala and Myrtus communis by colorimetric assay. Journal of Kerman University of Medical Sciences, 16(1): 32-42.
- Cerqueira Lima, G.S., Saraiva, P.G.C. and Saraiva, F.P., 2015. Current therapy of acquired ocular toxoplasmosis: a review. Journal of Ocular Pharmacology and Therapeutics, 31(9): 511-517.
- Dalimi, A. and Abdoli, A., 2012. Latent toxoplasmosis and human. Iranian Journal of Parasitology, 7: 1-17.
- Maenz, M., Schlüter, D., Liesenfeld, O., Schares, G., Gross, U. and Pleyer, U., 2014. Ocular toxoplasmosis past, present and new aspects of an old disease. Progress in Retinal and Eye Research, 39: 77-106.
- Mahboubi, M. and Ghazian Bidgoli, F., 2010. In vitro synergistic efficacy of combination of amphotericin B with Myrtus communis essential oil against clinical isolates of Candida albicans. Phytomedicine, 17(10): 771-774.
- Mahmoudvand, H., Ezzatkhah, F., Sharififar, F., Sharifi, I. and Dezaki, E.S., 2015a. Antileishmanial and cytotoxic effects of essential oil and methanolic extract of Myrtus communis L. Korean Journal of Parasitology, 53: 21-27.
- Mahmoudvand, H., Fallahi, S., Mahmoudvand, H., Shakibaie, M., Harandi, M.F. and Dezaki, E.S., 2015b. Efficacy of Myrtus communis L. to inactivate the hydatid cyst protoscoleces. Journal of Investigative Surgery, 29(3): 137-143.
- Maschke, M., Kastrup, O., Esser, S., Ross, B., Hengge, U. and Hufnagel, A., 2000. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). The Journal of Neurology, Neurosurgery, and Psychiatry, 69: 376-380.
- McLeod, R., Lykins, J., Noble, A.G., Rabiah, P., Swisher, C.N., Heydemann, P.T., McLone, D., Frim, D., Withers, S. and Clouser, F., 2014. Management of congenital toxoplasmosis. Current Pediatrics Reports, 2(3): 166-194.
- Milhau, G., Valentin, A., Benoit, F., Mallié, M., Bastide, J.-M., Pélissier, Y. and Bessière, J.M., 1997. In vitro antimalarial activity of eight essential oils. Journal of Essential Oil Research, 9: 329-333.
- Mimica-Dukić, N., Bugarin, D., Grbović, S., Mitić-Ćulafić, D., Vuković-Gačić, B., Orčić, D., Jovin, E. and Couladis, M., 2010. Essential oil of Myrtus communis L. as a potential antioxidant and antimutagenic agents. Molecules, 15(4): 2759-2770.
- Mohammadi, R., MIR Hendi Esfahani, S., Shadzi, S. and Moatar, F., 2008. Antifungal activity of Myrtus communis L. esssential oil against clinical isolates of Aspergillus. Journal of Isfahan Medical School, 26(89): 105-110.
- Montoya, J.G. and Liesenfeld, O., 2004. Toxoplasmosis. Lancet, 363(9425): 1965-1976.
- Neville, A.J., Zach, S.J., Wang, X., Larson, J.J., Judge, A.K., Davis, L.A., Vennerstrom, J.L. and Davis, P.H., 2015. Clinically available medicines demonstrating anti-toxoplasma activity. Antimicrobial Agents and Chemotherapy, 59(12): 7161-7169.
- Romani, A., Coinu, R., Carta, S., Pinelli, P., Galardi, C., Vincieri, F.F. and Franconi, F., 2004. Evaluation of antioxidant effect of different extracts of Myrtus communis L. Free Radical Research, 38: 97-103.
- Sumbul, S., Ahmad, M.A., Asif, M. and Akhtar, M., 2011. Myrtus communis Linn.: a review. Indian Journal of Natural Products and Resources, 2: 395-402.
- Valentini, P., Buonsenso, D., Barone, G., Serranti, D., Calzedda, R., Ceccarelli, M., Speziale, D., Ricci, R. and Masini, L., 2015. Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy. Journal of Perinatology, 35: 90-94.
- Vidal, J.E. and Oliveira, A.C., 2013. AIDS-related cerebral toxoplasmosis in São Paulo State, Brazil: marked improvements in the highly active antiretroviral therapy-era but the challenges continue. Brazilian Journal of Infectious Diseases, 17(3): 379-380.
- Wei, H.X., Wei, S.S., Lindsay, D.S. and Peng, H. J., 2015. A systematic review and meta-analysis of the efficacy of anti-toxoplasma gondii medicines in humans. PLoS One, 10: e0138204.
- Yan, J., Huang, B., Liu, G., Wu, B., Huang, S., Zheng, H., Shen, J., Lun, Z.-R., Wang, Y. and Lu, F., 2013. Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. Acta Tropica, 127(3): 236-244.